From the Guidelines
The recommended dose of Invokana (canagliflozin) for adults with type 2 diabetes is 100 mg once daily, taken before the first meal of the day, as supported by the most recent and highest quality study 1. This dose may be increased to 300 mg once daily if additional glycemic control is needed and the patient tolerates the lower dose well.
- Key considerations for dosing include:
- Patients with kidney impairment (eGFR less than 60 mL/min/1.73 m²) should not exceed 100 mg daily.
- Invokana is not recommended for patients with severe kidney impairment (eGFR less than 30 mL/min/1.73 m²) or those on dialysis.
- The medication works by inhibiting sodium-glucose cotransporter 2 (SGLT2) in the kidneys, which prevents glucose reabsorption and increases glucose excretion in urine, thereby lowering blood glucose levels.
- Patients should maintain adequate hydration while taking Invokana and be aware that common side effects include genital yeast infections, urinary tract infections, and increased urination, as noted in 1 and 1.
- Blood pressure monitoring is also important as Invokana can cause a modest reduction in blood pressure.
- It's essential to consider the patient's overall health, including their kidney function and cardiovascular risk, when determining the appropriate dose of Invokana, as emphasized in 1 and 1.
From the FDA Drug Label
2.2 Recommended Dosage and Administration Recommended Dosage for Glycemic Control in Adults and Pediatric Patients Aged 10 Years and Older The recommended starting dosage of INVOKANA is 100 mg orally once daily to improve glycemic control, taken before the first meal of the day For additional glycemic control, the dosage of INVOKANA may be increased to the maximum recommended dosage of 300 mg once daily
The recommended dose of Invokana (canagliflozin) for adults with type 2 diabetes is 100 mg orally once daily, which can be increased to a maximum of 300 mg once daily for additional glycemic control 2.
- The dosage may need to be adjusted based on renal function and other factors, such as concomitant use with UDP-Glucuronosyl transferase (UGT) enzyme inducers.
- It is essential to assess renal function before initiating INVOKANA and as clinically indicated.
From the Research
Invokana Dose for Adults with Type 2 Diabetes
The recommended dose of Invokana (canagliflozin) for adults with type 2 diabetes is:
- 100 mg once daily, taken before the first meal of the day 3, 4, 5, 6, 7
- The dose can be increased to 300 mg once daily for additional glycemic control 3, 4, 5, 6, 7
Key Considerations
- Canagliflozin can be used as monotherapy or in combination with other antihyperglycemic agents, such as metformin or sulfonylurea 3, 4, 5, 6, 7
- The dose of canagliflozin should be adjusted based on the patient's renal function and tolerance to the medication 3, 4, 5, 6, 7
- Canagliflozin has been shown to be effective in improving glycemic control, reducing body weight, and lowering blood pressure in adults with type 2 diabetes 3, 4, 5, 6, 7